Create Your Blog
  1. Home
  2. The Next Generation Immune Checkpoint Inhibitors And Stimulators Market Is Projected To Grow At An Annualized Rate Of ~15%, Till 2030

The Next Generation Immune Checkpoint Inhibitors And Stimulators Market Is Projected To Grow At An Annualized Rate Of ~15%, Till 2030

>

The next generation immune checkpoint inhibitors and stimulators market is projected to grow at an annualized rate of ~15%, till 2030

Roots Analysis has done a detailed study on Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030., covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this link

 

Key Market Insights

  • More than 150 industry players across the world are presently engaged in evaluating the potential of nearly 300 next generation immune checkpoint modulators for the treatment of multiple disease indications
  • The pipeline features a variety of marketed / clinical stage therapies, targeting a number of different types of immune checkpoints and being investigated for administration via different routes
  • In the last few years, over 600 clinical studies of various types of immune checkpoint modulation-based therapies, involving nearly 90,000 patients across different centers / hospitals, have been initiated worldwide
  • In the pursuit of obtaining an edge within this emerging and highly competitive market landscape, developers are actively exploring the therapeutic potential of novel immune checkpoints, beyond PD-L1, PD-1 and CTLA-4
  • Over time, big pharma players have initiated product development programs focused on immune checkpoint modulation for treating various oncological indications, investing significant capital, time and effort
  • Several organizations have extended financial support to aid research efforts in this domain; the current focus is on investigation of novel immune checkpoint pathways / targets
  • The growing interest in this field is also reflected by the 120+ partnerships have been signed in the last two years, involving both international and indigenous stakeholders
  • The future market, based on the revenue generation potential of marketed and late stage therapies, is anticipated to be distributed across different disease areas, mechanisms and key geographical regions
  • In the long term, the opportunity is likely to be segmented across diverse therapeutic modalities, immune checkpoint targets and routes of administration

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Table of Contents

 

  1. PREFACE
    1.1. Scope of the Report
    1.2.       Research Methodology
    1.3.       Chapter Outlines

    2.         EXECUTIVE SUMMARY

  2. INTRODUCTION
    3.1. Chapter Overview
    3.2.       Introduction to Cancer Immunotherapy
    3.3.       Fundamentals of Cancer Immunotherapy
    3.4.       Immune Checkpoint Modulators
    3.5.       First Generation Immune Checkpoint Modulators
    3.6.       Next Generation Immune Checkpoint Modulators
    3.6.1.    Types of Next Generation Immune Checkpoint Modulators

3.7.       Challenges-related to Immune Checkpoint Modulation-based Therapy
3.8.       Future Perspectives

 

  1. CURRENT MARKET LANDSCAPE: CLINICAL AND PRECLINICAL MOLECULES
    4.1.       Chapter Overview
    4.2.       Next Generation Immune Checkpoint Inhibitors and Stimulators: Marketed and Development        Pipeline

4.3.       Next Generation Immune Checkpoint Inhibitors and Stimulators: Pipeline Analysis
4.3.1.    Analysis by Phase of Development
4.3.2.    Analysis by Target Immune Checkpoint
4.3.3.    Analysis by Mechanism of Action
4.3.4.    Analysis by Therapeutic Modality
4.3.5.    Analysis by Route of Administration
4.3.6.    Analysis by Target Disease Indication
4.3.7.    Analysis by Therapeutic Area
4.3.8.    Analysis by Type of Therapy
4.3.9.    Funnel Representation: Analysis by Phase of Development, Mechanism of Action and Type of      Therapy

 

4.4.       Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers
4.4.1.    Analysis by Year of Establishment
4.4.2.    Analysis by Company Size and Geographical Location
4.4.3.    Leading Developer Companies: Analysis by Number of Pipeline Therapies
4.4.4.    World Map Representation: Analysis by Geography

 

Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com

Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis

Share:

Keywords: roots analysis,research,pharma,biotech,analysis,market research,industry reports,business report,global

Comments

WEBSITE SEO

Promote your website to Google #1 page.
Submit your website details to get free audit report
FREE BLOG/SBM SITES
Categories

Other related blogs

260 drug candidates are being evaluated in clinical / preclinical stages for the treatment of a wide variety of disease indications; the US has emerged as the major hub for microbiome-based research

By : Roots Analysis

The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical..

Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030, growing at an annualized rate of over 40%, claims Roots Analysis

By : Roots Analysis

Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic develop..

In Vitro ADME Testing Services Market, 2019-2030

By : Roots Analysis

To order this detailed 280+ page report, please visit this - https://www.rootsanalysis.com/reports/v..

Over 90 firms are actively involved in providing in vitro ADME testing services; of these, over 30 players claim to provide end-to-end services

By : Roots Analysis

ADME studies are considered to be critical in establishing the safety and efficacy of drug candidate..